Jacobs Levy Equity Management
CRNX icon

Jacobs Levy Equity Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,839
Closed -$525K – 1050
2021
Q2 		$525K Sell
27,839
-45,317
-62% -$796K ﹤0.01% 853
2021
Q1 		$1.12M Sell
73,156
-15,488
-17% -$240K 0.01% 715
2020
Q4 		$1.25M Buy
+88,644
New +$1.23M 0.01% 666

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Jacobs Levy Equity Management's CRNX Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2021, closing a stake of 27,839 shares — an estimated $525K sold.

Jacobs Levy Equity Management first reported a position in CRNX in Q4 2020 and held it in 3 quarters. The position peaked at $1.25M in Q4 2020. 94 funds tracked by Wall St. Rank hold CRNX as of Q3 2021.

  • Jacobs Levy Equity Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 27,839 Crinetics Pharmaceuticals shares in Q3 2021, an estimated $525K.
  • Jacobs Levy Equity Management first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Crinetics Pharmaceuticals position peaked at $1.25M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.